{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T15:13:20Z","timestamp":1776266000477,"version":"3.50.1"},"reference-count":18,"publisher":"Centre for Evaluation in Education and Science (CEON\/CEES)","issue":"4","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/BY\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Med Biochemistry"],"published-print":{"date-parts":[[2026]]},"abstract":"<jats:p>Background: The primary aim of this investigation was to build and test a novel risk prediction model incorporating plasma antithrombin III (ATIII) activity and thrombelastography (TEG)-derived parameters. This approach seeks to enhance the ability to stratify the risk of stroke recurrence among ischemic stroke (IS) patients receiving dual antiplatelet therapy (DAPT). Methods: In this prospective cohort study, 200 consecutive patients diagnosed with non-cardiogenic IS were recruited during a one-year period (May 2024 to May 2025). All participants had their ATIII activity, TEG parameters, and coagulation function indicators tested within 24-72 hours of DAPT commencement. After initial variable screening via univariate analysis. A logistic regression-based risk model was built, with its ability to distinguish outcomes evaluated using the receiver operating characteristic (ROC) curve. Results: Recurrent events occurred in 21.00% (42\/200) of cases within 3 months post-DAPT Multivariate analysis established ATIII, TEG-LY30, and D-Dimer as independent risk factors and TEG-MA as protective. The resultant model exhibited superior predictive power (A U C = 0.9480, 95% C I= 0.9l48~ 0.9813; sensitivity 90.48% , specificity 86.71%). Internal validation, yielding AUCs of 0.9521 in the training set and 0.9437 in the validation set, verified the model's strong generalizability. Subgroup evaluations further revealed the model's robust performance in both large artery atherosclerosis (AU C= 0.9505) and small vessel occlusion (AUC=0.9395) subtypes. Conclusions: Integrating ATIII activity with TEG parameters enables the development of a novel model to predict the risk of IS relapse following DAPT.<\/jats:p>","DOI":"10.5937\/jomb0-61916","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T09:21:30Z","timestamp":1761816090000},"page":"723-730","source":"Crossref","is-referenced-by-count":0,"title":["A novel risk prediction model for post-treatment ischemic stroke recurrence using plasma antithrombin III and thromboelastography"],"prefix":"10.5937","volume":"45","author":[{"given":"Yi","family":"Cheng","sequence":"first","affiliation":[{"name":"Huangshan Shoukang Hospital, Department of Transfusion Medicine, Huangshan, Anhui, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baobao","family":"Huang","sequence":"additional","affiliation":[{"name":"Huangshan Shoukang Hospital, Department of Transfusion Medicine, Huangshan, Anhui, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan","family":"Jiang","sequence":"additional","affiliation":[{"name":"Huangshan Shoukang Hospital, Department of Transfusion Medicine, Huangshan, Anhui, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3964","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Tu WJ, Zhao Z, Yin P, Cao L, Zeng J, Chen H, et al. Estimated Burden of Stroke in China in 2020. JAMA Netw Open 2023; 6(3): e231455;","DOI":"10.1001\/jamanetworkopen.2023.1455"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Sinnaeve PR, Adriaenssens T. Dual Antiplatelet Therapy De-escalation Strategies. Am J Cardiol 2021; 144 Suppl 1: S23-S31;","DOI":"10.1016\/j.amjcard.2020.12.020"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Valgimigli M, Gragnano F, Branca M, Franzone A, da Costa BR, Baber U, et al. Ticagrelor or Clopidogrel Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Systematic Review and Patient-Level Meta-Analysis. JAMA Cardiol 2024; 9(5): 437-48;","DOI":"10.1001\/jamacardio.2024.0133"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Valgimigli M, Landi A, Angiolillo DJ, Baber U, Bhatt DL, Bonaca MP, et al. Demystifying the Contemporary Role of 12-Month Dual Antiplatelet Therapy After Acute Coronary Syndrome. Circulation 2024; 150(4): 317-35;","DOI":"10.1161\/CIRCULATIONAHA.124.069012"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Liu L, Xie P, Zhu P, Zhuo W, A. Role of the score for the targeting of atrial fibrillation (STAF) combined with D-dimer in screening ischemic stroke patients with atrial fibrillation. J Med Biochem 2024; 43(1): 57-62;","DOI":"10.5937\/jomb0-44255"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Xu Q, Meng X, Li H, Xie X, Jing J, Lin J, et al. The Influence of Non-High-Density Lipoprotein Cholesterol on the Efficacy of Genotype-Guided Dual Antiplatelet Therapy in Preventing Stroke Recurrence. J Stroke 2024; 26(2): 231-41;","DOI":"10.5853\/jos.2024.00367"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Wang M, Yang Y, Wang Y, Luan M, Xu L, Zhong M, et al. Dual antiplatelet therapy in acute ischaemic stroke with or without cerebral microbleeds. Eur J Neurosci 2023; 57(7): 1197-207;","DOI":"10.1111\/ejn.15938"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Song P, Xie J, Li W, Zhang X, Sun Z, You C. Effect of plasma thrombin-antithrombin complex on ischemic stroke: a systematic review and meta-analysis. Syst Rev 2023; 12(1): 17;","DOI":"10.1186\/s13643-023-02174-9"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Chen F, Zhang L, Bai X, Wang X, Geng Z. Clinical Application of Thromboelastography in Acute Ischemic Stroke. Clin Appl Thromb Hemost 2022; 28: 10760296221131801;","DOI":"10.1177\/10760296221131801"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Jiang Y, Fan T. IL-6 and stroke recurrence in ischemic stroke. Biomark Med 2024; 18(17-18): 739-47;","DOI":"10.1080\/17520363.2024.2389038"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Suda T, Takatori H, Hayashi T, Kaji K, Nio K, Terashima T, et al. Plasma Antithrombin III Levels Can Be a Prognostic Factor in Liver Cirrhosis Patients with Portal Vein Thrombosis. Int J Mol Sci 2023; 24(9);","DOI":"10.3390\/ijms24097732"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"ElSaadani M, Ahmed SM, Jacovides C, Lopez A, Johnson VE, Kaplan LJ, et al. Antithrombin III ameliorates post-traumatic brain injury cerebral leukocyte mobilization enhancing recovery of blood brain barrier integrity. J Trauma Acute Care Surg 2021; 90(2): 274-80;","DOI":"10.1097\/TA.0000000000003000"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Tormene D, Noventa F, Campello E, Gavasso S, Marobin M, Turatti G, et al. The risk of arterial thrombosis in carriers of natural coagulation inhibitors: a prospective family cohort study. Internal and Emergency Medicine 2021; 16(4): 997-1003;","DOI":"10.1007\/s11739-021-02656-5"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Luo JQ, Mao SS, Chen JY, Ke XY, Zhu YF, Huang W, et al. Antithrombin III deficiency in a patient with recurrent venous thromboembolism: A case report. World J Clin Cases 2023; 11(20): 4956-60;","DOI":"10.12998\/wjcc.v11.i20.4956"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Fuja C, Carll TC, Mikrut K, Wool GD. Sensitivity and specificity of thromboelastography for hyperfibrinolysis: Comparison of TEG 5000 and TEG 6S CK LY30 systems. Am J Clin Pathol 2023; 160(5): 455-65;","DOI":"10.1093\/ajcp\/aqad068"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Emani S, Donahue R, Callender A, Ghebremichael M, Nathan M, Ibla JC, et al. Thromboelastography-guided Intraoperative Platelet Transfusion in Pediatric Heart Surgery. The Annals of Thoracic Surgery 2024; 118(6): 1271-8;","DOI":"10.1016\/j.athoracsur.2024.09.003"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Wang Y, Li L, Hu X, Huang L, Li Z. The value of thromboelastography in evaluating the efficacy of Xueshuantong combined with edaravone in the treatment of acute cerebral infarction. Medicine (Baltimore) 2024; 103(17): e37954;","DOI":"10.1097\/MD.0000000000037954"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Tayal D, Jain P, Goswami B. D-dimer - a multifaceted molecule. Horm Mol Biol Clin Investig 2024; 45(2): 75-84;","DOI":"10.1515\/hmbci-2022-0093"}],"container-title":["Journal of Medical Biochemistry"],"original-title":["Novi model predvi\u0111anja rizika za recidiv ishemijskog mo\u017edanog udara nakon le\u010denja kori\u0161\u0107enjem plazma antitrombina III i tromboelastografije"],"language":"en","link":[{"URL":"https:\/\/scindeks-clanci.ceon.rs\/data\/pdf\/1452-8258\/2026\/1452-82582604723C.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T14:20:20Z","timestamp":1776262820000},"score":1,"resource":{"primary":{"URL":"https:\/\/scindeks.ceon.rs\/Article.aspx?artid=1452-82582604723C"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5937\/jomb0-61916","relation":{},"ISSN":["1452-8258","1452-8266"],"issn-type":[{"value":"1452-8258","type":"print"},{"value":"1452-8266","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]}}}